Medera News, Researches and Articles

About us

We do not want children to die from a disease that can be cured. We want to give hope to families and ensure that all children with DMD are treated and regain their health.

Latest Articles

Sarepta Therapeutics Halts ELEVIDYS Shipments for Non-Ambulatory DMD Patients

Press Releases July 16, 2025 0

Due to two documented incidents of severe liver failure...

Medera and University of Kansas Medical Center Announce First Patient Treated in Pioneering Gene Therapy Trial (SRD-001) for Duchenne Muscular Dystrophy Associated Cardiomyopathy

Research July 15, 2025 0

Medera a clinical-stage biopharmaceutical company focused on targeting cardiovascular...

Mutations Amenable to Exon 50 Skipping Therapies in Duchenne Muscular Dystrophy

DMD July 11, 2025 0

Duchenne muscular dystrophy (DMD) is a severe genetic disorder...

Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy

Approved Treatments December 26, 2024 5

A genetic condition known as Duchenne muscular dystrophy (DMD)...

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

Research January 5, 2025 5

The results of new gene therapy studies for Duchenne...

Duchenne Muscular Dystrophy: Treatment & Cost

Editorials January 2, 2025 1

The excitement you feel until your child is born...

Medera

Must Read

Tevard Biosciences to Present Data Demonstrating tRNA-based Therapy Rescued Full-Length Dystrophin and Motor Function in Duchenne Muscular Dystrophy Model

EMA Recommends EU Approval for Duvyzat (givinostat) to Treat Duchenne Muscular Dystrophy

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy